Prolonging thrombin production

How ApcinteX’s modified serpin could treat both hemophilia A and B

ApcinteX Ltd. is betting that inhibiting an endogenous brake on thrombin production will generate a therapy for hemophilia A and B that can be used by patients who have developed neutralizing antibodies to factor replacement therapies and those who have pre-existing immunity to gene therapy vectors. And because the target is active only at injury sites, it should be safer than other alternatives to factor replacement now in the clinic.

Hemophilia is caused by mutations in the coagulation enzymes

Read the full 788 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE